z-logo
open-access-imgOpen Access
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis
Author(s) -
Karen Cohen,
Gilles Van Cutsem,
Andrew Boulle,
Helen McIlleron,
Eric Goemaere,
Philip Smith,
Gary Maartens
Publication year - 2007
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkm484
Subject(s) - nevirapine , cmin , medicine , pharmacokinetics , cmax , rifampicin , pharmacology , reverse transcriptase inhibitor , combination therapy , tuberculosis , immunology , viral load , antiretroviral therapy , human immunodeficiency virus (hiv) , pathology
Nevirapine-containing antiretroviral therapy (ART) and rifampicin-based antitubercular therapy are commonly co-administered in Africa, where nevirapine is often the only available non-nucleoside reverse transcriptase inhibitor. Rifampicin induces the metabolism of nevirapine, but the extent of the reduction in nevirapine concentrations has varied widely in previous studies. We describe the steady-state pharmacokinetics of nevirapine during and after antitubercular therapy in South African patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom